{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T07:51:35Z","timestamp":1769673095466,"version":"3.49.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","funder":[{"name":"Ramsay Hospital Research Foundation Australia","award":["2020\/PRE\/0001"],"award-info":[{"award-number":["2020\/PRE\/0001"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Major depressive disorder (MDD) and bipolar disorder (BD) are common, disabling conditions. Despite associated morbidity and premature mortality, current treatments have modest efficacy and response to treatment highly variable. Contributing factors to variability in response include influence of common genetic variations in the pharmacokinetic and\/or pharmacodynamic action of medications. As such, attention has turned toward the identification of genetic markers that could assist with determining who will respond or not to psychotropic treatment. Results of studies to date are promising but primarily have been small. This study aims to evaluate the efficacy of a pharmacogenetic (PGx)-based decision support tool among adults with MDD and BD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-site, single (rater) blinded, randomized controlled trial with two arms evaluates the 24-week efficacy of a PGx-based support tool for adults with MDD or BD. Participants are randomized to receive PGx testing or standard prescribing. Participants provide DNA samples at baseline, but only those (including clinicians) randomized to the former receive the results at the start of their study participation. It is not mandatory for clinicians to follow the test recommendations. Remission rate (primary outcome), change in depression symptoms, drop-out rate, medication adherence, and medication side effects (secondary outcomes) are assessed at 4-, 8-, 12-, and 24-week postbaseline by a blinded rater. Analyses will follow an intention-to-treat approach and use mixed models for repeated measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Treatment response to medication for severe mood disorders is highly variable and less than optimal. This trial will provide evidence as to whether a PGx-based support tool is an efficacious strategy to inform selection and dosing of pharmacotherapy among adults with severe mood disorders. Importantly, it will do so independently and with a larger sample size than previous studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This trial is registered under the number ACTRN12621001374853 (11 Oct 2021).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000585","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:00:23Z","timestamp":1765836023000},"page":"63-70","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenetic testing versus standard prescribing of psychotropics for the treatment of severe mood disorders: A randomized controlled trial protocol"],"prefix":"10.1097","volume":"36","author":[{"given":"Malcolm","family":"Hopwood","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Melbourne Medical School, University of Melbourne, Parkville"},{"name":"Professorial Research Unit, Ramsay Clinic Albert Road, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Komiti","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Melbourne Medical School, University of Melbourne, Parkville"},{"name":"Professorial Research Unit, Ramsay Clinic Albert Road, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Hurley","sequence":"additional","affiliation":[{"name":"Professorial Research Unit, Ramsay Clinic Albert Road, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad A.","family":"Bousman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Melbourne Medical School, University of Melbourne, Parkville"},{"name":"Departments of Medical Genetics, Psychiatry, Physiology & Pharmacology, and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"R2-20260128","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"392","year":"2018","journal-title":"The Lancet"},{"key":"R3-20260128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3949\/ccjm.75.1.57","article-title":"The STAR*D study: treating depression in the real world.","volume":"75","author":"Gaynes","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"R4-20260128","first-page":"10m00979","article-title":"Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study.","volume":"13","author":"Thase","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"key":"R5-20260128","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/appi.ajp.161.2.217","article-title":"Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials.","volume":"161","author":"Geddes","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R6-20260128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cpr.2018.07.005","article-title":"Risk factors for relapse and recurrence of depression in adults and how they operate: a four-phase systematic review and meta-synthesis.","volume":"64","author":"Buckman","year":"2018","journal-title":"Clin Psychol Rev"},{"key":"R7-20260128","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/appi.ajp.163.2.217","article-title":"Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).","volume":"163","author":"Perlis","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R8-20260128","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1001\/jama.1983.03340240025024","article-title":"Predictors of relapse in major depressive disorder.","volume":"250","author":"Keller","year":"1983","journal-title":"JAMA"},{"key":"R9-20260128","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.eurpsy.2009.11.012","article-title":"Predicting the course and outcome of bipolar disorder: a review.","volume":"25","author":"Treuer","year":"2010","journal-title":"Eur Psychiatry"},{"key":"R10-20260128","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/a-1288-1061","article-title":"Review and consensus on pharmacogenomic testing in psychiatry.","volume":"54","author":"Bousman","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"R11-20260128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-3956(98)00004-1","article-title":"Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees.","volume":"32","author":"Franchini","year":"1998","journal-title":"J Psychiatr Res"},{"key":"R12-20260128","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12888-017-1412-1","article-title":"Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.","volume":"17","author":"P\u00e9rez","year":"2017","journal-title":"BMC Psychiatry"},{"key":"R13-20260128","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.cll.2008.05.006","article-title":"Pharmacogenetics-guided dose modifications of antidepressants.","volume":"28","author":"Seeringer","year":"2008","journal-title":"Clin Lab Med"},{"key":"R14-20260128","doi-asserted-by":"crossref","first-page":"150","DOI":"10.9758\/cpn.2015.13.2.150","article-title":"Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report.","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"R15-20260128","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1038\/tp.2012.115","article-title":"ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.","volume":"2","author":"Singh","year":"2012","journal-title":"Transl Psychiatry"},{"key":"R16-20260128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuron.2007.11.017","article-title":"Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression.","volume":"57","author":"Uhr","year":"2008","journal-title":"Neuron"},{"key":"R17-20260128","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2215-0366(16)00017-1","article-title":"Commercial pharmacogenetic-based decision-support tools in psychiatry.","volume":"3","author":"Bousman","year":"2016","journal-title":"The Lancet Psychiatry"},{"key":"R18-20260128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S1092852913000436","article-title":"The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study.","volume":"19","author":"Breitenstein","year":"2014","journal-title":"CNS Spectr"},{"key":"R19-20260128","first-page":"219","article-title":"A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.","volume":"16","author":"Winner","year":"2013","journal-title":"Discov Med"},{"key":"R20-20260128","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/cts.12986","article-title":"Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: a randomized controlled trial.","volume":"14","author":"Papastergiou","year":"2021","journal-title":"Clin Transl Sci"},{"key":"R21-20260128","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/archpsyc.1991.01810330020003","article-title":"The definition and operational criteria for treatment outcome of major depressive disorder. A review of the current research literature.","volume":"48","author":"Prien","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"R22-20260128","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change.","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"R23-20260128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity.","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"R24-20260128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0165-0327(01)00451-7","article-title":"Defining remission by cut off score on the MADRS: selecting the optimal value.","volume":"72","author":"Hawley","year":"2002","journal-title":"J Affect Disord"},{"key":"R25-20260128","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4088\/JCP.v65n0204","article-title":"Defining remission on the Montgomery-Asberg depression rating scale.","volume":"65","author":"Zimmerman","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R26-20260128","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00004850-200211000-00003","article-title":"Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Rating Scale and the Clinical Global Impressions Rating Scale in antidepressant clinical trials.","volume":"17","author":"Khan","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"R27-20260128","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","article-title":"Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA).","volume":"192","author":"Williams","year":"2008","journal-title":"Br J Psychiatry"},{"key":"R28-20260128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4088\/JCP.v66n0116","article-title":"A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder.","volume":"66","author":"Bowden","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R29-20260128","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1176\/appi.ajp.161.6.1057","article-title":"Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.","volume":"161","author":"Hirschfeld","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R30-20260128","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/chi.0b013e3180335ae4","article-title":"Response and remission in adolescent mania: signal detection analyses of the young mania rating scale.","volume":"46","author":"Patel","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R31-20260128","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","article-title":"Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group.","volume":"57","author":"Tohen","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R32-20260128","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"R33-20260128","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3928\/0048-5713-20020901-06","article-title":"The PHQ-9: a new depression diagnostic and severity measure.","volume":"32","author":"Kroenke","year":"2002","journal-title":"Psychiatric Annals"},{"key":"R34-20260128","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","article-title":"Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.","volume":"282","author":"Spitzer","year":"1999","journal-title":"JAMA"},{"key":"R35-20260128","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1007\/s11606-007-0333-y","article-title":"Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis.","volume":"22","author":"Gilbody","year":"2007","journal-title":"J Gen Intern Med"},{"key":"R36-20260128","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/00005650-200412000-00006","article-title":"Monitoring depression treatment outcomes with the patient health questionnaire-9.","volume":"42","author":"L\u00f6we","year":"2004","journal-title":"Med Care"},{"key":"R37-20260128","first-page":"420","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.","volume":"16","author":"Cipriani","year":"2018","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"R38-20260128","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive validity of a medication adherence measure in an outpatient setting.","volume":"10","author":"Morisky","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R39-20260128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijchp.2014.11.003","article-title":"Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting.","volume":"15","author":"De Las Cuevas","year":"2015","journal-title":"Int J Clin Health Psychol"},{"key":"R40-20260128","doi-asserted-by":"crossref","first-page":"722","DOI":"10.26719\/2015.21.10.722","article-title":"Reliability and known-group validity of the Arabic version of the 8-item Morisky Medication Adherence Scale among type 2 diabetes mellitus patients.","volume":"21","author":"Ashur","year":"2015","journal-title":"East Mediterr Health J"},{"key":"R41-20260128","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.sapharm.2013.10.006","article-title":"The 8-item Morisky medication adherence scale: validation of a Brazilian-Portuguese version in hypertensive adults.","volume":"10","author":"de Oliveira-Filho","year":"2014","journal-title":"Res Social Adm Pharm"},{"key":"R42-20260128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5539\/gjhs.v7n4p173","article-title":"Validation of the Persian version of the 8-item Morisky medication adherence scale (MMAS-8) in Iranian hypertensive patients.","volume":"7","author":"Moharamzad","year":"2015","journal-title":"Glob J Health Sci"},{"key":"R43-20260128","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.seizure.2014.01.003","article-title":"Validation of Chinese version of the Morisky medication adherence scale in patients with epilepsy.","volume":"23","author":"Yang","year":"2014","journal-title":"Seizure"},{"key":"R44-20260128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00131746-200603000-00002","article-title":"Self-rated global measure of the frequency, intensity, and burden of side effects.","volume":"12","author":"Wisniewski","year":"2006","journal-title":"J Psychiatr Pract"},{"key":"R45-20260128","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.","volume":"152","author":"Schulz","year":"2010","journal-title":"Ann Intern Med"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:00:16Z","timestamp":1769626816000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000585","relation":{},"ISSN":["1744-6872","1744-6880"],"issn-type":[{"value":"1744-6872","type":"print"},{"value":"1744-6880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"2025-05-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}